A5070492885- Lipoproteins and Cardiovascular Health
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Neural and Behavioral Psychology Studies
- Tea Polyphenols and Effects
- Antioxidant Activity and Oxidative Stress
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Research Studies
- Transcranial Magnetic Stimulation Studies
- Lipid metabolism and disorders
- Complement system in diseases
- Platelet Disorders and Treatments
- Glycosylation and Glycoproteins Research
- Phytochemical Studies and Bioactivities
- Drug Transport and Resistance Mechanisms
- Renal Diseases and Glomerulopathies
- ATP Synthase and ATPases Research
- Proteoglycans and glycosaminoglycans research
- Nutritional Studies and Diet
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Angiogenesis and VEGF in Cancer
- Seaweed-derived Bioactive Compounds
- Cholangiocarcinoma and Gallbladder Cancer Studies
Inner Mongolia Medical University
2024
Peking University
2023
Peking University Cancer Hospital
2023
Regeneron (United States)
2015-2023
Guangzhou Medical University
2023
Shandong University
2020-2022
Shandong Provincial Hospital
2021
Shandong First Medical University
2021
Hospital of Hebei Province
2020
Shunyi Hospital of Beijing Traditional Chinese Medicine Hospital
2017
To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally tolerated lipid-lowering therapy (LLT). In two randomized, double-blind studies (ODYSSEY FH I, n = 486; II, 249), were randomized 2 : 1 to 75 mg or placebo every weeks (Q2W). Alirocumab dose was increased at Week 12 150 Q2W if 8 ≥1.8 mmol/L (70 mg/dL). Primary endpoint (both studies) percentage change calculated from baseline 24....
J o u r n a l P e -p f patients in the iruplinalkib group (median PFS, 27.7 months [95% CI, crizotinib group; HR, 0.34 [98.02% 0.23-0.52];p<0.0001).The ORR assessed by IRC was 93.0% (95% 87.5-96.6) and 89.3% 83.1-93.7) group.The intracranial 90.9% (10/11, 95% 58.7-99.8) 60.0% (9/15, 32.3-83.7) for with measurable baseline CNS metastases.Incidence of grade 3 or 4 treatment-related adverse events 51.7% 49.7% group.Interpretation: Iruplinalkib demonstrated significantly improved PFS antitumor...
Background: Tea consumption has been associated with decreased cardiovascular risk, but potential mechanisms of benefit are ill-defined.While epidemiologic studies suggest that drinking multiple cups tea per day lowers lowdensity lipoprotein cholesterol (LDL-C), previous trials and administration green extract have failed to show any impact on lipids lipoproteins in humans.Our objective was study the a theaflavinenriched subjects mild moderate hypercholesterolemia.Methods: Double-blind,...
In previous phase III studies, the PCSK9 monoclonal antibody alirocumab was administered at doses of 75 or 150 mg every 2 weeks (Q2W). CHOICE I (NCT01926782) evaluated 300 4 (Q4W) in patients on either maximally tolerated statin no statin, both ± other lipid-lowering therapies.CHOICE included with hypercholesterolemia moderate-to-very-high cardiovascular risk. Patients were randomized to Q4W, Q2W (calibrator arm), placebo for 48 weeks, dose adjustment arm Week (W) 12 if W8 LDL-C levels...
Accumulating studies have shown that high-frequency (HF) repetitive transcranial magnetic stimulation (rTMS) may improve cognitive dysfunction of the patients with schizophrenia (SCZ), but inconsistent results. The present study aims to assess efficacy different frequencies neuronavigated rTMS in ameliorating impairments and alleviating psychotic symptoms. A total 120 were randomly assigned 3 groups: 20 Hz (n = 40), 10 or sham 40) for 8 weeks, then followed up at week 32. Repeatable Battery...
Abstract Cognitive impairment is a central aspect of schizophrenia (SCZ) that occurs at the onset disease and related to poor social function outcome in patients with SCZ. Recent literatures have revealed repetitive transcranial magnetic stimulation (rTMS) be one efficient medical interventions for cognitive impairments. However, no study has been conducted investigate treatment effectiveness 20 Hz rTMS neuronavigation system administered left dorsolateral prefrontal cortex (DLPFC)...
// Yan-Rong Liu 1, * , Lan Liang 3, Jian Min Zhao 4, Yang Zhang 5, 2 Wei-Long Zhong Qiang Jun-Jie Wei Meng Li Jie Yuan Shuang Chen 1 Shu-Min Zong Hui-Juan Jing Qin Bo Sun Hong-Gang Zhou Tao and Cheng Tianjin Key Laboratory of Molecular Drug Research, International Joint Academy Biomedicine, Tianjin, China State Medicinal Chemical Biology College Pharmacy, Nankai University, 3 GoalGen Biotechnology Co., Ltd., 4 Pathology Department, Shun Yi District Hospital, Beijing, 5 Department...
•ODYSSEY ALTERNATIVE assessed alirocumab (ALI) in statin-intolerant patients.•ALI significantly reduced low-density lipoprotein cholesterol during the double-blind treatment period.•The open-label period ALI long-term safety.•Skeletal muscle events were reported by 38.4% of patients with statin-intolerance period.•ALI was well tolerated and produced durable reductions over 3 years. BackgroundThe 24-week randomized, ODYSSEY trial (NCT01709513) demonstrated significant (LDL-C) PCSK9 inhibitor...
Pain is the common indicator of inflammatory ailments and traumatic tissue injuries. The dieckol an important therapeutic compound, which present in many seaweeds. research work was planned to assess anti-inflammatory anti-nociceptive actions by using animal model. action investigated acetic acid triggered writhing, formalin provoked nociception, tail immersion test, hot-plate methods effects explored carrageenan paw edema method. In investigation administration remarkably suppressed...
Introduction: Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare genetic lipid disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease, underscoring the need for early aggressive treatment. Evinacumab, angiopoietin-like 3 inhibitor, significantly reduced LDL-C in patients with HoFH a pivotal Phase trial (NCT03399786). The current study assesses long-term safety efficacy of evinacumab HoFH. Methods: This...
Background: Hypertriglyceridemia (HTG) is the consequence of elevated triglyceride-rich lipoproteins (TGRLs) containing apolipoprotein B (apoB), such as VLDL and chylomicrons. Epidemiological genetic studies indicate that triglycerides (TGs) cholesterol within TGRLs causally contribute to coronary heart disease risk (CHD). Evinacumab (EVIN), an angiopoietin-like 3 inhibitor, lowers TGs by derepressing lipoprotein lipase (LPL) endothelial activity. In a Phase 2 trial in patients (pts) with...